Aileron Therapeutics, Inc.

Aileron Therapeutics (NASDAQ:ALRN) is a clinical-stage biopharmaceutical company that is discovering and developing novel medicines to improve the outcomes and the quality of life of cancer patients by targeting high-value and historically undruggable targets using their proprietary platform of stabilized cell-permeating peptides. Their lead product candidate, ALRN-6924, is a cell-permeating…More peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2. Their focus at Aileron is the clinical development of ALRN-6924 to protect cancer patients against chemotherapy-induced toxicities, a novel concept they call “chemoprotection.”